Your browser doesn't support javascript.
Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature.
Samim, M M; Dhar, Debjyoti; Arshad, Faheem; Anudeep, D D S; Patel, Vishal G; Neeharika, Sriram Ramalakshmi; Dhamija, Kamakshi; Ravindranath, Chowdary Mundlamuri; Yadav, Ravi; Raja, Pritam; Netravathi, M; Menon, Deepak; Holla, Vikram V; Kamble, Nitish L; Pal, Pramod K; Nalini, Atchayaram; Vengalil, Seena.
  • Samim MM; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Dhar D; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Arshad F; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Anudeep DDS; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Patel VG; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Neeharika SR; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Dhamija K; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Ravindranath CM; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Yadav R; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Raja P; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Netravathi M; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Menon D; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Holla VV; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Kamble NL; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Pal PK; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Nalini A; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India.
  • Vengalil S; Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India. Electronic address: seenavengalil@gmail.com.
J Clin Neurosci ; 108: 37-75, 2023 Feb.
Article in English | MEDLINE | ID: covidwho-2165608
ABSTRACT

BACKGROUND:

Recent studies have shown various neurological adverse events associated with COVID-19 vaccine.

OBJECTIVE:

We aimed to retrospectively review and report the neurological diseases temporally associated with COVID-19 vaccine.

METHODS:

We performed a retrospective chart review of admitted patients from 1st February 2021 to 30th June 2022. A total of 4672 medical records were reviewed of which 51 cases were identified to have neurological illness temporally associated with COVID-19 vaccination.

RESULTS:

Out of 51 cases, 48 had probable association with COVID-19 vaccination while three had possible association. Neurological spectrum included CNS demyelination (n = 39, 76.5 %), Guillain-Barré-syndrome (n = 3, 5.9 %), stroke (n = 6, 11.8 %), encephalitis (n = 2, 3.9 %) and myositis (n = 1, 2.0 %). Female gender had a greater predisposition (FM, 1.131). Neurological events were more commonly encountered after the first-dose (n = 37, 72.5%). The mean latency to onset of symptoms was 13.2 ± 10.7 days after the last dose of vaccination. COVIShield (ChAdOx1) was the most commonly administered vaccine (n = 43, 84.3 %). Majority of the cases with demyelination were seronegative (n = 23, 59.0 %) which was followed by anti-Myelin oligodendrocyte-glycoprotein associated demyelination (MOGAD) (n = 11, 28.2 %) and Neuromyelitis optica (NMOSD) (n = 5, 12.8 %). Out of 6 Stroke cases, 2 cases (33.3 %) had thrombocytopenia and coagulopathy. At discharge, 25/51 (49.0 %) of the cases had favourable outcome (mRS 0 to 1). Among six patients of stroke, only one of them had favourable outcome.

CONCLUSION:

In this series, we describe the wide variety of neurological syndromes temporally associated with COVID-19 vaccination. Further studies with larger sample size and longer duration of follow-up are needed to prove or disprove causality association of these syndromes with COVID-19 vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / Stroke / COVID-19 / Nervous System Diseases Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: J Clin Neurosci Journal subject: Neurology Year: 2023 Document Type: Article Affiliation country: J.jocn.2022.12.015

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Neuromyelitis Optica / Stroke / COVID-19 / Nervous System Diseases Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: J Clin Neurosci Journal subject: Neurology Year: 2023 Document Type: Article Affiliation country: J.jocn.2022.12.015